Shopping Cart 0
Cart Subtotal
USD 0

MediPoint: Viscosupplementation-Global Analysis and Market Forecasts

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 6495

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 12990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 19485
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

MediPoint: Viscosupplementation-Global Analysis and Market Forecasts

Summary

The global viscosupplementation market was estimated atUSD2.1B in 2016 across the 39 markets covered in this report. By the end of the forecast period in 2023, GlobalData estimates the market will grow to approximatelyUSD3.1B at a Compound Annual Growth Rate (CAGR) of 6.0%.

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability around the world. Resulting from a complex interaction of biomechanical, biochemical, and genetic factors, OA develops slowly and is characterized by the degradation of the affected joint's cartilage and bone hypertrophy. The disability is accompanied by joint pain, stiffness, and loss of range of motion. Initially treated with various therapies including physical therapy and nonsteroidal anti-inflammatory drugs (NSAIDs), advanced cases of OA have traditionally been treated surgically. However, intra-articular viscosupplementation with hyaluronic acid (HA), a high-molecular-weight glycosaminoglycan, has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade.

Scope

Outlook of sales volume, pricing trends, revenue trends with 2016 as base year and forecasts until 2023, for viscosupplementation.

Company share analysis in 2016, for viscosupplementation.

Market insights and competitive assessment of the key players within the viscosupplementation market.

Reasons to buy

Identify the unmet needs and understand physicians' perceptions of the current viscosupplementation products

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global viscosupplementation market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors

READ MORE

Table Of Content

Scope

Table of Contents

1 About the Authors

1.1 Analysts

1.1.1 Jennifer Ryan, Orthopedic Analyst, Medical Devices

2 Table of Contents

2.1 List of Tables

2.2 List of Figures

3 Executive Summary

3.1 Overview

3.2 Market Dynamics

3.3 Key Players in the Viscosupplementation Market

3.4 Viscosupplementation Market Future Outlook

4 Introduction

4.1 Catalyst

4.2 Related Reports

4.3 Upcoming Related Reports

5 Market Outlook

5.1 Procedure Trends

5.2 Pricing Trends

5.3 Revenue Trends

5.4 Company Share Analysis

6 Market Insights

6.1 North America

6.1.1 Canada

6.1.2 Mexico

6.1.3 US

6.2 Europe

6.2.1 Denmark, Finland, Norway, and Sweden

6.2.2 Belgium, France, and Netherlands

6.2.3 Germany and Switzerland

6.2.4 UK and Ireland

6.2.5 Italy, Portugal, and Spain

6.2.6 Austria, Czech Republic, Hungary, and Poland

6.2.7 Greece, Russia, and Turkey

6.3 APAC

6.3.1 Australia and New Zealand

6.3.2 China and Taiwan

6.3.3 India

6.3.4 Japan

6.3.5 South Korea

6.4 South America

6.4.1 Brazil

6.4.2 Argentina and Chile

6.5 Middle East and Africa

6.5.1 Israel

6.5.2 South Africa

6.5.3 Egypt, Saudi Arabia, and UAE

7 Competitive Assessment

7.1 Overview

7.2 Anika Therapeutics

7.2.1 Overview

7.2.2 Portfolio Assessment

7.2.3 Competitive Positioning

7.3 Chugai Pharmaceutical

7.3.1 Overview

7.3.2 Portfolio Assessment

7.3.3 Competitive Positioning

7.4 Ferring Pharmaceuticals

7.4.1 Overview

7.4.2 Portfolio Assessment

7.4.3 Competitive Positioning

7.5 Fidia Farmaceutici

7.5.1 Overview

7.5.2 Portfolio Assessment

7.5.3 Competitive Positioning

7.6 Meda AB (Mylan)

7.6.1 Overview

7.6.2 Portfolio Assessment

7.6.3 News and Deals Analysis

7.6.4 Competitive Positioning

7.7 Sanofi

7.7.1 Overview

7.7.2 Portfolio Assessment

7.7.3 Competitive Positioning

7.8 Seikagaku Corporation

7.8.1 Overview

7.8.2 Portfolio Assessment

7.8.3 Competitive Positioning

7.9 Other Players

8 Appendix

8.1 Bibliography

8.2 Abbreviations

8.3 Methodology

8.3.1 Overview

8.3.2 Coverage

8.3.3 Secondary Research

8.3.4 Forecasting Methodology

8.3.5 Primary Research Summary

8.4 About MediPoint

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer


List Of Figure

List of Figures

Figure 1: Viscosupplementation Sales for North America, by Country, 2016 and 2023

Figure 2: Viscosupplementation Sales for Europe, by Country, 2016 and 2023

Figure 3: Viscosupplementation Sales for APAC, by Country, 2016 and 2023

Figure 4: Viscosupplementation Sales for South America, by Country, 2016 and 2023

Figure 5: Viscosupplementation Sales for the Middle East and Africa, by Country, 2016 and 2023


List Of Table

List of Tables

Table 1: Key Metrics in the Global Viscosupplementation Market

Table 2: North America Viscosupplementation Volume Forecast, 2023

Table 3: Europe Viscosupplementation Volume Forecast, 2023

Table 4: APAC Viscosupplementation Volume Forecast, 2023

Table 5: South America Viscosupplementation Volume Forecast, 2023

Table 6: Middle East and Africa Viscosupplementation Volume Forecast, 2023

Table 7: North America Viscosupplementation Average Selling Price Forecast (USD ), 2023

Table 8: Europe Viscosupplementation Average Selling Price Forecast (USD ), 2023

Table 9: APAC Viscosupplementation Average Selling Price Forecast (USD ), 2023

Table 10: South America Viscosupplementation Average Selling Price Forecast (USD ), 2023

Table 11: Middle East and Africa Viscosupplementation Average Selling Price Forecast (USD ), 2023

Table 12: North America Viscosupplementation Market Revenue Forecast (USD M), 2023

Table 13: Europe Viscosupplementation Market Revenue Forecast (USD M), 2023

Table 14: APAC Viscosupplementation Market Revenue Forecast (USD M), 2023

Table 15: South America Viscosupplementation Market Revenue Forecast (USD M), 2023

Table 16: Middle East and Africa Viscosupplementation Market Revenue Forecast (USD M), 2023

Table 17: North America Viscosupplementation Company Share Analysis, 2016

Table 18: Europe Viscosupplementation Company Share Analysis, 2016

Table 19: APAC Viscosupplementation Company Share Analysis, 2016

Table 20: South America Viscosupplementation Company Share Analysis, 2016

Table 21: Middle East and Africa Viscosupplementation Company Share Analysis, 2016

Table 22: Anika Therapeutics-Key Marketed Products Assessment 4

Table 23: Chugai Pharmaceutical-Key Marketed Products Assessment 4

Table 24: Ferring Pharmaceuticals-Key Marketed Products Assessment

Table 25: Fidia Farmaceutici-Key Marketed Products Assessment

Table 26: Fidia Farmaceutici-Key Clinical Trials

Table 27: Meda AB-Key Marketed Products Assessment

Table 28: Sanofi-Key Marketed Products Assessment

Table 29: Seikagaku Corporation-Key Marketed Products Assessment 54

Table 30: Seikagaku Corporation-Key Pipeline Products Assessment 55

Table 31: Summary of Other Players in the Viscosupplementation Market, 2017 56

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Anika Therapeutics

Chugai Pharmaceutical

Ferring Pharmaceuticals

Fidia Farmaceutici

Meda AB (Mylan)

Sanofi

Seikagaku Corporation